Nonhemostatic Adverse Effects of Anticoagulants and Antiplatelet Agents

 

 Buy Article Permissions and Reprints

Abstract

The topic of adverse effects of drugs is now receiving due attention in both the lay and medical communities. For drugs of the coagulation disorder class, such as anticoagulants and antiplatelet agents, the obvious adverse effects are bleeding from a dose too high and thrombosis from a dose too low. However, these drugs have other potential adverse effects that are not directly related to blood coagulation, yet cannot be dismissed due to their medical importance. There has been a recent advancement of several new drugs in this category and this number will soon grow as more drugs are reaching the end of their clinical trials. This article will discuss the nonhemostatic adverse effects of anticoagulants and antiplatelet drugs. As the adverse effects of bleeding and thrombosis will be excluded, this article will be in contrast to the typical discussions on the anticoagulant and antiplatelet drug classes.

• References

• 1 Loscalzo J, Schafer AI. Overview of hemostasis and fibrinolysis. In: Sasahara AA, Loscalzo J, , eds. New Therapeutic Agents in Thrombosis and Thrombolysis. 2nd revised ed.. New York: Marcel Dekker; 2003: 1-7
  Google Scholar
• 2 Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326 (12) 800-806
  CrossrefPubMedGoogle Scholar
• 3 Pillinger MH, Capodici C, Rosenthal P , et al. Modes of action of aspirin-like drugs: salicylates inhibit Erk activation and integrin-dependent neutrophil adhesion. Proc Natl Acad Sci U S A 1998; 95 (24) 14540-14545
  CrossrefPubMedGoogle Scholar
• 4 van Oijen MGH, Dieleman JP, Laheij RJF, Sturkenboom MC, Jansen JB, Verheugt FW. Peptic ulcerations are related to systemic rather than local effects of low-dose aspirin. Clin Gastroenterol Hepatol 2008; 6 (3) 309-313
  CrossrefPubMedGoogle Scholar
• 5 Temple AR. Acute and chronic effects of aspirin toxicity and their treatment. Arch Intern Med 1981; 141 (3 Spec No) 364-369
  CrossrefPubMedGoogle Scholar
• 6 Fleisher GR, Ludwig S. Textbook of Pediatric Emergency Medicine. Philadelphia, PA: Lippincott Williams & Wilkins; 2010
  Google Scholar
• 7 Kozer E, Nikfar S, Costei A, Boskovic R, Nulman I, Koren G. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol 2002; 187 (6) 1623-1630
  CrossrefPubMedGoogle Scholar
• 8 Ostensen M, Ramsey-Goldman R. Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options?. Drug Saf 1998; 19 (5) 389-410
  CrossrefPubMedGoogle Scholar
• 9 Pregnancy Registries FDA. 7_Medicine and Pregnancy.indd. Available at: http://google2.fda.gov/search?q=cache:bradT4FMCX8J:www.fda.gov/downloads/ForConsumers/ByAudience/ForWomen/UCM121913.pdf+aspirin+pregnancy&client=FDAgov&lr=&proxystylesheet=FDAgov&output=xml_no_dtd&ie=UTF-8&site=FDAgov&access=p&oe=UTF-8 . Accessed January 14, 2012.
  PubMedGoogle Scholar
• 10 Becker ML, Leeder JS. Identifying genomic and developmental causes of adverse drug reactions in children. Pharmacogenomics 2010; 11 (11) 1591-1602
  CrossrefPubMedGoogle Scholar
• 11 Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB. Reye's syndrome in the United States from 1981 through 1997. N Engl J Med 1999; 340 (18) 1377-1382
  CrossrefPubMedGoogle Scholar
• 12 Pugliese A, Beltramo T, Torre D. Reye's and Reye's-like syndromes. Cell Biochem Funct 2008; 26 (7) 741-746
  CrossrefPubMedGoogle Scholar
• 13 Hurwitz ES, Barrett MJ, Bregman D , et al. Public Health Service study of Reye's syndrome and medications. Report of the main study. JAMA 1987; 257 (14) 1905-1911
  CrossrefPubMedGoogle Scholar
• 14 Department of Health and Ageing. Australia's regulatory authority for therapeutic goods. Review of aspirin/Reye's syndrome warning statement. Available at: www.tga.gov.au . Accessed April 1, 2012.
  PubMedGoogle Scholar
• 15 Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB. Reye's syndrome in the United States from 1981 through 1997. N Engl J Med 1999; 340 (18) 1377-1382
  CrossrefPubMedGoogle Scholar
• 16 Becker ML, Leeder JS. Identifying genomic and developmental causes of adverse drug reactions in children. Pharmacogenomics 2010; 11 (11) 1591-1602
  CrossrefPubMedGoogle Scholar
• 17 Pearlman BL, Gambhir R. Salicylate intoxication: a clinical review. Postgrad Med 2009; 121 (4) 162-168
  CrossrefPubMedGoogle Scholar
• 18 Proudfoot AT, Krenzelok EP, Vale JA. Position paper on urine alkalinization. J Toxicol Clin Toxicol 2004; 42 (1) 1-26
  CrossrefPubMedGoogle Scholar
• 19 Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129 (5) 394-405
  CrossrefPubMedGoogle Scholar
• 20 Bennett CL, Kiss JE, Weinberg PD , et al. Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet 1998; 352 (9133) 1036-1037
  CrossrefPubMedGoogle Scholar
• 21 Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA 1999; 281 (9) 806-810
  CrossrefPubMedGoogle Scholar
• 22 Cosmi B, Rubboli A, Castelvetri C, Milandri M. Ticlopidine versus oral anticoagulation for coronary stenting. Cochrane Database Syst Rev 2001; (4) CD002133
  PubMedGoogle Scholar
• 23 Sanofi-aventis. PLAVIX^® (clopidogrel bisulfate) tablets prescribing information. Available at: http://products.sanofi.us/PLAVIX/PLAVIX.html . Accessed January 16, 2012.
  PubMedGoogle Scholar
• 24 Makkar K, Wilensky RL, Julien MB, Herrmann HC, Spinler SA. Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents. Ann Pharmacother 2006; 40 (6) 1204-1207
  CrossrefPubMedGoogle Scholar
• 25 Zakarija A, Bandarenko N, Pandey DK , et al. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 2004; 35 (2) 533-537
  CrossrefPubMedGoogle Scholar
• 26 Oppedijk B, Odekerken DAM, van der Wildt JJ, Melissant CF. Rapid oral desensitisation procedure in clopidogrel hypersensitivity. Neth Heart J 2008; 16 (1) 21-23
  CrossrefPubMedGoogle Scholar
• 27 Wong PF, Chong LY, Mikhailidis DP, Robless P, Stansby G. Antiplatelet agents for intermittent claudication. Cochrane Database Syst Rev 2011; 11 (11) CD001272
  PubMedGoogle Scholar
• 28 Eli Lilly. Acute coronary syndrome - percutaneous coronary intervention - EffientHCP.com (prasugrel) tablets. Available at: http://www.effienthcp.com/Pages/index.aspx?WT.srch=1&WT.mc_id=EffHSACPEfL2056-75508 . Accessed January 26, 2012.
  PubMedGoogle Scholar
• 29 Montalescot G, Wiviott SD, Braunwald E , et al; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373 (9665) 723-731
  CrossrefPubMedGoogle Scholar
• 30 James S, Akerblom A, Cannon CP , et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009; 157 (4) 599-605
  CrossrefPubMedGoogle Scholar
• 31 AstraZeneca. BRILINTATM (ticagrelor) tablets, For health care professionals. Available at: http://www.brilintatouchpoints.com/?source=BRLDH10675&umedium=cpc&uadpub=Google&ucampaign=B_BRILINTA_HCP_Branded_2.0&ucreative=Prescribing_Information&pkw=ticagrelor%20package%20insert&WT.mc_id=BRLDH10675#ISI . Accessed January 26, 2012.
  PubMedGoogle Scholar
• 32 Millennium Pharmaceuticals. INTEGRILIN^® (eptifibatide) injection. Available at: http://www.integrilin.com/integrilin/index.html . Accessed January 27, 2012.
  PubMedGoogle Scholar
• 33 Medicure. Aggrastat tirofiban HCl. Available at: http://www.medicure.com/aggrastat/aggrastat.html . Accessed January 27, 2012.
  PubMedGoogle Scholar
• 34 Eli Lilly and Company. ReoPro.com - safety. Available at: http://www.reopro.com/Pages/safety.aspx . Accessed January 27, 2012.
  PubMedGoogle Scholar
• 35 Fareed J, Thethi I, Hoppensteadt D. Old versus new oral anticoagulants: focus on pharmacology. Annu Rev Pharmacol Toxicol 2012; 52: 79-99
  CrossrefPubMedGoogle Scholar
• 36 Chan YC, Valenti D, Mansfield AO, Stansby G. Warfarin induced skin necrosis. Br J Surg 2000; 87 (3) 266-272
  CrossrefPubMedGoogle Scholar
• 37 Rose VL, Kwaan HC, Williamson K, Hoppensteadt D, Walenga J, Fareed J. Protein C antigen deficiency and warfarin necrosis. Am J Clin Pathol 1986; 86 (5) 653-655
  PubMedGoogle Scholar
• 38 Ng T, Tillyer ML. Warfarin-induced skin necrosis associated with Factor V Leiden and protein S deficiency. Clin Lab Haematol 2001; 23 (4) 261-264
  CrossrefPubMedGoogle Scholar
• 39 Sallah S, Thomas DP, Roberts HR. Warfarin and heparin-induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment. Thromb Haemost 1997; 78 (2) 785-790
  PubMedGoogle Scholar
• 40 Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF. Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med 2006; 166 (2) 241-246
  CrossrefPubMedGoogle Scholar
• 41 Pubmed Health. Warfarin. Available at: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000634/ . Accessed January 28, 2012.
  PubMedGoogle Scholar
• 42 Ehrenforth S, Schenk JF, Scharrer I. Liver damage induced by coumarin anticoagulants. Semin Thromb Hemost 1999; 25 (1) 79-83
  Article in Thieme ConnectPubMedGoogle Scholar
• 43 Messmore HL, Fabbrini N, Bird ML , et al. Simple scoring system for early management of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2011; 17 (2) 197-201
  CrossrefPubMedGoogle Scholar
• 44 Bick RL, Frenkel EP, Walenga J, Fareed J, Hoppensteadt DA. Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use. Hematol Oncol Clin North Am 2005; 19 (1) 1-51 , v
  CrossrefPubMedGoogle Scholar
• 45 GSKsource. ARIXTRA (fondaparinux sodium) injection. Available at: http://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=ProductDetailPage&product_id=1244136744215&featureKey=600552#nlmhighlights . Accessed January 28, 2012.
  PubMedGoogle Scholar
• 46 Goldfarb MJ, Blostein MD. Fondaparinux in acute heparin-induced thrombocytopenia: a case series. J Thromb Haemost 2011; 9 (12) 2501-2503
  CrossrefPubMedGoogle Scholar
• 47 GSKsource. Argatroban injection. Available at: http://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=ProductDetailPage&product_id=1244136535577&featureKey=600551 . Accessed January 28, 2012.
  PubMedGoogle Scholar
• 48 Bayerhealthcare. REFLUDAN^® (lepirudin (rDNA) for injection. Available at: http://berlex.bayerhealthcare.com/html/products/pops/therapeutic3.html . Accessed January 28, 2012.
  PubMedGoogle Scholar
• 49 Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003; 108 (17) 2062-2065
  CrossrefPubMedGoogle Scholar
• 50 Lubenow N, Eichler P, Lietz T, Greinacher A. HIT Investigators Group. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005; 3 (11) 2428-2436
  CrossrefPubMedGoogle Scholar
• 51 The Medicines Co. Angiomax^® (bivalirudin) for injection. Available at: http://www.angiomax.com/ . Accessed January 28, 2012.
  PubMedGoogle Scholar
• 52 Frenkel EP, Shen Y-M, Haley BB. The direct thrombin inhibitors: their role and use for rational anticoagulation. Hematol Oncol Clin North Am 2005; 19 (1) 119-145 , vi–vii
  CrossrefPubMedGoogle Scholar
• 53 Boehringer Ingelheim. Side effects & adverse reactions | PRADAXA - dabigatran etexilate. Available at: http://www.pradaxapro.com/adverse-reactions.jsp . Accessed January 28, 2012.
  PubMedGoogle Scholar
• 54 Hohnloser SH, Oldgren J, Yang S , et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012; 125 (5) 669-676
  CrossrefPubMedGoogle Scholar
• 55 Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172 (5) 397-402
  CrossrefPubMedGoogle Scholar
• 56 Agnelli G, Gallus A, Goldhaber SZ , et al; ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007; 116 (2) 180-187
  CrossrefPubMedGoogle Scholar
• 57 Bayer Schering Pharma AG. Summary of product characteristics Xarelto. Available at: http://www.xarelto.com/en/information-on-xarelto/summary_of_product_characteristics/index.php . Accessed February 26, 2011.
  PubMedGoogle Scholar
• 58 Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365 (21) 2002-2012
  CrossrefPubMedGoogle Scholar
• 59 Wahi R, Rao G, Thethi I. Pathak. Prevalence of free methyl chloride as an impurity in generic clopidogrel preparations. Safety implications in cardiovascular patients. Circulation 2010; 122 : Abstract No. 17290
  PubMedGoogle Scholar